IDH1 and oligodendroglioma: We identified all patients with likely 1p/19q-codeleted oligodendrogliomas, IDH-wildtype glioblastomas, and IDH-mutant astrocytomas in the REMBRANDT study in an effort to make the REMBRANDT study a better resource for validating diffuse glioma research.